Diabetic Macular Edema

CoTx-10 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Research on aflibercept 8 mg reveals promising real-world outcomes for treating wet AMD and diabetic macular edema, enhancing vision and safety.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

The trial will be evaluating AXPAXLI dosed every 6 months vs aflibercept (2 mg) dosed every 8 weeks in treatment-naive patients with wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases.

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology.

Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

Kodiak Sciences reveals promising APEX study results for KSI-101, showing significant vision improvement in macular edema patients.

A study reveals significant treatment burdens for patients with AMD and DME, highlighting the need for improved education and support to enhance outcomes.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.

ANI Pharmaceuticals releases results for ILUVIEN in treating diabetic macular edema.

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.